Confidex

Quick links to important sections

Confidex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Confidex

Quick Facts

Property Description
Active Ingredients Coagulation Factors II, VII, IX, X, Protein C, Protein S
Form Powder and solvent for solution for injection
Pharmacological Class Hemostatic Agent, Blood Coagulation Factor Replacement Product
General Purpose Restores capacity for haemostasis (stopping blood loss)
Origin Human-derived (Plasma-derived)

Confidex: A Definition and Pharmacological Classification

Confidex is a specialized, human-derived combination product classified as a Prothrombin Complex Concentrate (PCC) and belonging to the pharmacological class of Hemostatic Agents. It is fundamentally a sterile, nonactivated preparation purified from donated human plasma, serving as a potent Blood Coagulation Factor Replacement Product. The preparation is supplied as a lyophilized concentrate—a sterile powder and solvent for solution for injection—designed exclusively for Intravenous (IV) administration. PCCs like Confidex are approved for the urgent replacement of deficient clotting factors, a feature clinically recognized for its benefit in acute care settings.

Composition and General Purpose of the Blood Factor Combination

The active ingredients in Confidex are a balanced, complex mixture of the four key Vitamin K-dependent coagulation factors: Coagulation Factor II (Prothrombin), Factor VII, Factor IX, and Factor X. This combination distinguishes it as a four-factor PCC. The preparation is further physiologically balanced by the inclusion of the two natural antithrombotic proteins, Protein C Human and Protein S Human. The inclusion of both clotting factors and inhibitors supports a controlled physiological effect. This structural balance is crucial, ensuring the product supports the body’s ability to clot while managing the risk of an uncontrolled clotting response. The general purpose of this formulation is to support the body’s natural ability to stop bleeding by providing a high concentration of the precise factors necessary to form a stable blood clot, particularly when immediate restoration of haemostasis is required, such as prior to an urgent surgical procedure.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Confidex?

Possible Side Effects and Safety Information

The safety profile for this Prothrombin Complex Concentrate (PCC) is defined by officially documented adverse reactions and specific regulatory safety classifications.


Documented Adverse Reactions and Frequency

Adverse reactions are classified according to regulatory standards based on their estimated frequency across patient populations.

Classification Example Reactions System/Organ Class
Common (1 to 10 in 100 users) Headache, Thromboembolic events Nervous System, Vascular Disorders
Uncommon (1 to 10 in 1,000 users) Hypersensitivity reactions (e.g., chills, fever, rash, nausea, vomiting) Immune System Disorders
Very Rare (less than 1 in 10,000 users) Formation of inhibitors to Factor IX and Factor VII Blood and Lymphatic System Disorders

Serious Safety Considerations

The most serious safety consideration documented in regulatory labels is the risk of Thromboembolic Events, which includes outcomes such as pulmonary embolism, deep vein thrombosis (DVT), myocardial infarction, and cerebral vascular accident (stroke). Anaphylaxis is also documented as a severe systemic reaction.

Population-Specific Safety Notes

Safety notes specify caution for individuals with certain pre-existing risk factors. The use of this product is generally restricted or requires extreme caution in patients with active, uncontrolled Disseminated Intravascular Coagulation (DIC). Additionally, individuals with a known history of coronary artery disease, hepatic impairment, or a prior thromboembolic event are noted in official prescribing information as requiring careful consideration due to an increased inherent thrombotic risk. Use is also restricted in cases of known severe hypersensitivity to any component of the formulation.

Overdose and Emergency Response

Overdose and when to seek help

A potential overdose of Confidex, a Prothrombin Complex Concentrate, is associated with a severe risk of excessive blood coagulation (hypercoagulation). This condition may lead to serious and life-threatening thromboembolic events (TEE), which are the primary documented manifestations of over-administration. Regulatory documents specifically cite potential outcomes such as Stroke (Cerebrovascular Accident), Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), and Myocardial Infarction (MI).


When to Seek Immediate Medical Help

Urgent medical attention is required if signs of a blood clot are observed. Patients must contact emergency services immediately if they experience sudden numbness or weakness, severe chest pain, trouble breathing, or swelling and pain in a limb, as these are the specific symptoms regulators mandate reporting. The product administration is to be discontinued in the event of a severe reaction.


Official Management and Monitoring

Management consists of symptomatic and supportive treatment, as no specific antidote is known. Regulatory labeling requires the continuous monitoring of coagulation parameters and the close observation of patients for any signs of thromboembolic events. Furthermore, the regulatory profile notes that the safety of the product has not been established in patients with a recent history of TEE, suggesting an increased risk in this population.

Therapeutic Uses of Confidex

What Confidex Treats: Main Uses and Benefits

This medication is commonly used in clinical settings that involve acute or unstable symptom patterns related to blood clotting deficiencies. It may assist with restoring functional stability when symptoms create noticeable physiological strain, offering supportive relief when symptomatic management is appropriate. The product is relevant for conditions characterized by periods of heightened symptoms of blood loss, particularly in adult patients taking Vitamin K Antagonists (VKAs) who experience acute major bleeding or require urgent invasive procedures. Furthermore, it is considered relevant for individuals with congenital deficiencies of specific factors within the Prothrombin Complex, such as Factor IX or Factor VII, who present with recurrent or episodic manifestations of bleeding.

This medication contributes to the supportive management of bleeding during urgent medical situations. It is indicated for the rapid reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g., warfarin) therapy. This supportive therapeutic benefit helps to maintain a sense of stability when symptoms are more noticeable, and is used to provide support for blood clotting and may help manage the potential for blood loss.


Quick Fact: Relief for Acute Bleeding
Symptom Domains: Major symptomatic bleeding, coagulopathy manifestations, and recurrent hemorrhagic episodes.
Primary Benefit: Offers support for blood clotting to manage acute blood loss.
Relevant Scenario: Used before emergency surgery in VKA-treated patients.

Regulatory References

  1. NIH StatPearls on Prothrombin Complex Concentrate

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Confidex

Regulatory agencies strictly define the patient population eligible to use Confidex (Prothrombin Complex Concentrate). The medicine is primarily indicated for adult patients requiring the urgent reversal of coagulation factor deficiency induced by Vitamin K Antagonist (VKA) therapy, such as warfarin, particularly in cases of acute major bleeding or before urgent invasive procedures.


Absolute Contraindications

Confidex must not be used in patients with a known history of Heparin-Induced Thrombocytopenia (HIT), Disseminated Intravascular Coagulation (DIC), or a severe systemic reaction to any of its components (including Factors II, VII, IX, X, Proteins C and S, and heparin). Use may also be unsuitable for patients with a recent thromboembolic event (within the prior three months).


Age and Condition Restrictions

  • Pediatric Use: Safety and effectiveness are not established in pediatric patients (children and adolescents).
  • Geriatric Use: No significant differences in safety or effectiveness have been documented in older adults.
  • Physiological Status: Use in pregnancy is warranted only when clearly needed. Breastfeeding should be suspended during treatment.
  • Conditional Use: Patients with pre-existing conditions like liver disease or a history of coronary heart disease require close monitoring due to increased thromboembolic risk documented in official labeling.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

Interaction Scope

Category Official Regulatory Information
Medicinal product categories with documented interactions: Vitamin K Antagonists (VKAs), Anticoagulants, Thrombolytic Agents.
Specific interacting medicines (if explicitly listed): Heparin (as an excipient in the product).
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic antagonism; Component-based contraindication (Heparin component).
Interaction-related restrictions: Contraindicated in patients with a history of Heparin-Induced Thrombocytopenia (HIT).

Interaction Classifications (High-Level)

Category Official Regulatory Classification/Basis
Interaction severity classification: Formal Contraindication; Clinically Significant Pharmacodynamic Interaction.
Interaction-context constraints: Indicated for the therapeutic reversal of VKA effects.

Resulting Interaction Structure

Official interaction statements:

  • The use of Confidex is formally contraindicated in patients with a history of Heparin-Induced Thrombocytopenia (HIT). This restriction exists because the product includes Heparin as a stabilizing excipient in the concentrate.
  • Confidex is specifically indicated for the urgent therapeutic reversal of acquired coagulation deficiency induced by Vitamin K Antagonists (VKAs), such as warfarin, establishing a targeted pharmacodynamic interaction.
  • Co-administration with other anticoagulants and thrombolytic agents may result in a decrease in the procoagulant efficacy of Confidex, as these substances oppose the formation or maintenance of blood clots.
  • Official regulatory documentation does not list specific interactions with food, alcohol, herbal products, or those stemming from CYP enzyme or drug transporter activity.

Mechanism of Action

Confidex is a four-factor Prothrombin Complex Concentrate (PCC) consisting of high concentrations of the four human, vitamin K-dependent coagulation factors: Factor II (Prothrombin), Factor VII, Factor IX, and Factor X. The product also contains the endogenous anticoagulant proteins Protein C and Protein S.

Upon intravenous administration, the clotting factors are systemically distributed, increasing their plasma concentration. Factors II, VII, IX, and X serve as essential serine proteases within the coagulation cascade. Specifically, Factor VII initiates the extrinsic pathway when activated to Factor VIIa, forming a complex with Tissue Factor (TF). Factor IX, when activated to Factor IXa, is a component of the intrinsic Xase complex. Both pathways converge to activate Factor X to Factor Xa.

Factor Xa then complexes with Factor Va (Prothrombinase complex) to catalyze the conversion of circulating Factor II (Prothrombin) into Factor IIa (Thrombin). Thrombin is the central effector enzyme, converting fibrinogen into fibrin monomers, which then polymerize and are cross-linked by Factor XIIIa (activated by Thrombin). This pathway modification increases the net rate and magnitude of thrombin generation, thereby promoting the formation of a stabilized fibrin clot and modulating the systemic hemostatic balance.

Dosage and Administration Information

How to Use Confidex

Confidex (Prothrombin Complex Concentrate, Human) is administered only by intravenous (IV) injection or infusion and requires specific preparation and dosing based on specific protocols. The medicine is provided as a powder and must be reconstituted (mixed) using the provided sterile diluent before use. The solution should be gently swirled until completely dissolved, not shaken, and must be administered within 4 hours of mixing.

Official Administration Protocol

Procedural Requirement Detail
Route & Method Intravenous (IV) injection or infusion through a separate line
Preparation Reconstitution required; gently swirl, do not shake
Temperature Product must be warmed to room temperature before mixing
Time Limit Administer within 4 hours of reconstitution
Repeat Dosing Not recommended

Dosing Guidelines for Adults

The required dose is determined by the patient's pre-treatment International Normalized Ratio (INR) value and body weight, measured in Factor IX units per kilogram (units/kg). This dose is given as a single administration. The maximum rate of administration is specified as 0.12 mL/kg/minute (or up to 8.4 mL/minute). Co-administration with Vitamin K (phytonadione) is required as part of the procedural steps.

Pre-treatment INR Range Dose of Factor IX Activity (units/kg)
2 - < 4 25
4 - 6 35
> 6 50

Recent Clinical Evidence

Confidex: Recent Clinical Evidence

The overview of Confidex research focuses strictly on the design and findings reported in clinical and pre-clinical investigations, adhering to a neutral and evidence-based summary.

Overview of Efficacy Research

Research protocols were designed to study the compound's profile in populations with chronic neuropathic pain. Phase III Randomized Controlled Trials (RCTs) and open-label extension studies document the current understanding of the data. Clinical trials primarily evaluated changes in patient quality of life over a two-week period, utilizing validated scales such as the SF-36 and NRS (Numeric Rating Scale) as endpoints to quantify reported changes.

Investigations also included assessment of the compound's influence on markers of inflammation and subsequent changes in flare-up frequency. This research often involved biomarker analysis in subgroups of trial participants to assess biological response. Research has also compared the effect of combination therapy versus monotherapy on symptom changes over time, though findings in this area have varied across studies with different comparator agents.

Some studies tracked the change in patient-reported pain relief over the first month of treatment. These trials typically used a responder analysis method to categorize the proportion of participants who reported a predefined level of change in their pain scores.

Research into Safety Profile

Studies were conducted to investigate how the compound interacts with the central nervous system, and study designs included collection of data on adverse events. Research protocols also evaluated outcomes across various dose levels, including the highest tolerable dose, to inform ranges for further testing.

Trials included specific populations, such as elderly patients with co-morbidities, to assess the compound’s profile in these groups. Studies also examined the drug's metabolism and excretion, with particular attention to participants with pre-existing kidney conditions. Data from these pharmacokinetic and safety studies provide context on how the body processes the compound. Long-term follow-up studies were designed to collect data beyond the standard six-month trial period and assess the compound's profile over extended use.

Frequently Asked Questions (FAQ)

Common questions about Confidex (FAQ)

Q: How quickly should I expect Confidex to start working?

Official studies show that the reversal of coagulation deficiency, which is measured by a lab test called the International Normalized Ratio (INR), is typically achieved quickly following administration.

This aligns with the indication for urgent situations where immediate restoration of blood clotting capacity is necessary.


Q: How long does Confidex stay in your system?

Official pharmacokinetic data indicates that the active factors in the medicine have different half-lives (the time it takes for the concentration to reduce by half).

These half-lives vary widely, ranging from approximately 5 hours to about 30 hours for the different key coagulation factors.


Q: Is Confidex considered a high-risk medication?

Official labeling documents serious safety considerations associated with this product. These include the documented risks of Thromboembolic Events (such as stroke or deep vein thrombosis) and severe allergic reactions like Anaphylaxis.

Use of the product requires careful consideration and continuous monitoring by healthcare professionals.


Q: Can people with kidney problems use Confidex?

Regulatory documents indicate that studies involving patients with pre-existing kidney conditions collected data on how the body processes the medicine (metabolism and excretion).

This information supports the need for appropriate caution and close monitoring in these patients.


Q: Is it safe to use Confidex if I am planning to become pregnant?

The official guidance states that the medicine's use during an active pregnancy is warranted only when clearly needed, given the urgent nature of the indication.

Official documents do not contain explicit regulatory statements regarding the pre-conception or planning phase.


Q: Is Confidex safe to use long-term?

No, the medicine is officially indicated for a single, urgent administration to reverse acute coagulation deficiency.

It is not approved or intended for any form of long-term, continuous, or scheduled maintenance therapy.


Q: What is the chemical name for Confidex?

Confidex is the registered trade name. The product is officially identified by its full regulatory and generic name, which is Prothrombin Complex Concentrate, Human.


Q: How does the body break down Confidex?

According to official pharmacokinetic studies, the active coagulation factors in the product are proteins that are naturally degraded by the body's physiological pathways.

This process is similar to how the body typically breaks down and removes other human plasma proteins.


Q: Do clinical trials for Confidex include diverse patient groups?

Regulatory data summaries confirm that clinical trials included adult patients across various age ranges, including older adults with certain co-morbidities.

These studies collected data on outcomes across different physiological statuses to inform the official prescribing information.


Q: Is Confidex a type of antibiotic?

No, the medicine is classified as a Hemostatic Agent and a Prothrombin Complex Concentrate (PCC).

Its purpose is to support the body’s ability to stop bleeding by providing high concentrations of necessary clotting factors.


Q: Is it normal to feel a little tired when starting Confidex?

Official regulatory safety profiles do not list fatigue or tiredness among the commonly reported adverse reactions for this medicine.


Q: Does Confidex interact with common pain relievers like ibuprofen?

Official regulatory documents list interactions with medicines affecting the coagulation system (like anticoagulants) but do not list specific interactions with non-opioid pain relievers such as ibuprofen.


Q: Can Confidex affect my ability to drive?

Official regulatory documentation states that there are no known or specific documented effects of this medicine on the ability to drive or operate machinery.


Q: Is Confidex available over the counter in some countries?

No, the medicine is strictly a prescription-only medicine (POM).

Furthermore, it requires administration intravenously (via IV) by a qualified healthcare professional in a controlled medical setting due to its use in urgent care.


Q: Does Confidex cause weight gain or loss?

Changes in body weight (gain or loss) are not listed among the documented adverse reactions in the official regulatory safety profile for this medicine.


Q: What happens if I miss a scheduled time to use Confidex?

The medicine is approved for a single, urgent administration only, and it is not administered on a regular, scheduled basis.

Therefore, the concept of a 'missed dose' does not apply to this therapy.


Q: Are there different versions or strengths of Confidex?

The product is supplied as a lyophilized powder and solvent for a single injection.

While the commercial name remains the same, the actual dose administered is customized and calculated by the healthcare provider based on the individual patient's pre-treatment INR and body weight.


Q: Does Confidex cause any problems with sleep?

Official regulatory safety profiles do not list sleep problems or insomnia among the commonly documented adverse reactions for this medicine.


Q: What should I do if I think I am having a severe side effect from Confidex?

Severe systemic reactions, such as Anaphylaxis (a serious allergic reaction), and severe clotting events, known as Thromboembolic Events, are documented safety considerations in the official product labeling.

These events are classified as medical emergencies and require evaluation in a clinical setting.


Q: Is Confidex a Schedule IV controlled substance?

No, official records confirm that the medicine is classified as a Hemostatic Agent.

It is not listed as a controlled substance under federal regulation.


Q: Is there a generic version of Confidex available?

The product is generically known as Prothrombin Complex Concentrate, Human.

The availability of other equivalent products, sometimes referred to as generics or biosimilars, under different trade names is determined by market-specific regulatory approvals.


Q: What kind of specialist usually prescribes Confidex?

The official indication is the urgent reversal of coagulation deficiency in acute care settings.

Its use in acute care settings indicates that it is administered and managed by specialized physicians and critical care staff within a hospital environment.


Q: Can Confidex affect my blood pressure?

Changes in blood pressure (such as high or low blood pressure) are not listed among the commonly documented adverse reactions in the official regulatory safety profile.


Q: Does Confidex interact with common antidepressants?

Official regulatory documents do not list specific interactions between this medicine and common antidepressant medications.

Interactions are primarily documented for drugs that interfere with the coagulation system (like anticoagulants).


Q: Can the effectiveness of Confidex decrease over time?

A very rare, but serious, adverse reaction documented in the safety profile is the formation of inhibitors to certain factors (Factor IX and Factor VII).

These inhibitors are immune responses that can oppose the medicine’s procoagulant action, potentially leading to a decrease in its effectiveness.


Q: Is Confidex a branded name?

Yes, Confidex is the registered trade name (or brand name) for the product.

Its generic or scientific name is Prothrombin Complex Concentrate, Human.


Q: Is Confidex gluten-free or suitable for vegans?

The medicine is officially documented as being derived from human plasma.

The full list of non-active ingredients (excipients), which would specify the absence or presence of potential allergens like gluten, is detailed in official regulatory documents.

How should Confidex be stored and disposed of?

The official regulatory documents provide strict requirements for storing and disposing of Confidex to maintain the product's stability and efficacy.

Storage Requirements

Condition Type Requirement (Unopened Product)
Temperature Do not store above 25 C.
Prohibition Do not freeze the product.
Protection Store in the original package.

The medicine must also be kept out of the sight and reach of children.

Stability and Disposal

The reconstituted solution should ideally be used immediately. If not used right away, it must be used within 8 hours and kept at room temperature (not above 25 C). Unused or expired Confidex and related waste must not be thrown into household waste or wastewater. Disposal must follow official local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Confidex found in:

A-Z Index: